Evidence map›Paper›PMID 25671432›Full record

ArticlePloS one2015

Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients.

Ingrid Holst Olsen, Nanna Holt, Seppo W Langer, Jane P Hasselby, Henning Grønbæk, Jens Hillingsø, Masti Mahmoud, Morten Ladekarl, Lene H Iversen, Andreas Kjær and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Goblet cell carcinoid of the appendix: Six case reports.World journal of clinical cases · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ingrid Holst OlsenDepartment of Surgical Gastroenterology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Oncology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Pathology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Endocrinology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Nanna HoltDepartment of Hepatology and Gastroenterology, European NET Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.
Seppo W LangerDepartment of Oncology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Jane P HasselbyDepartment of Pathology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Henning GrønbækDepartment of Hepatology and Gastroenterology, European NET Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.
Jens HillingsøDepartment of Surgical Gastroenterology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Masti MahmoudDepartment of Surgical Gastroenterology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Morten LadekarlDepartment of Oncology, European NET Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.
Lene H IversenDepartment of Surgery, European NET Centre of Excellence, Aarhus University Hospital, Aarhus, Denmark.
Andreas KjærDepartment of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Birgitte H FederspielDepartment of Pathology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Ulrich KniggeDepartment of Surgical Gastroenterology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Endocrinology, European NET Centre of Excellence, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Aarhus University Hospital · DKRigshospitalet · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAppendiceal goblet cell carcinoids (GCCs) exhibit neuroendocrine and adenocarcinoma features. PATIENTS AND

methodsAnalysis of demography, pathology, prognostic markers, treatment and survival in 83 GCC patients (f/m: 56/27) diagnosed 1992-2013.

resultsMedian age for f/m was 59/58 years, respectively, and similar for localized and disseminated disease. At diagnosis 54 patients had localized appendiceal disease (f/m: 29/25). According to TNM 24% had Stage I, 70% had Stage II and 6% had Stage III. Twenty-nine patients had disseminated disease (f/m: 27/2). Chromogranin A, synaptophysin and p53 were positive in >90%. Serotonin was positive in 70%. Median Ki67 index was 32% (6-75%) and higher in Tang group C (50%) compared to group A (30%; p<0.0001), and group B (30%; p<0.004). All patients had surgery. Sixty-three (76%) had radical resections including all patients with localized disease. Median OS was 83 months. The 1-, 5- and 10-year survival rates were 90%, 58%, and 38%, respectively. For localized disease OS was 164 months and 1-, 5- and 10-year survival rates were 100%, 80%, and 55%, respectively. For disseminated disease OS was 19 months and 1-, 5- and 10-year survival rates were 73%, 18% and 6%, respectively. The 1-, 5- and 10 year-survival rates for f/m were 87%/96%, 49%/76% and 31%/57%, respectively (p = 0.02). According to the Tang classification group A, B, and C OS was 118, 83 and 20 months, respectively (p = 0.0002).

conclusionThe Tang classification was found to be a significant prognostic factor, while the Ki67 index was not. Localized GCCs occurred equally in males and females, while disseminated GCCs were mostly seen in females. Median age of patients with localized disease and disseminated disease was identical. Cox regression analysis found Stage IV, focally positive synaptophysin and non-radical surgery as strongest negative prognostic factors.

Indexed as

AdultAgedCarcinoid TumorCohort StudiesDatabases, FactualDenmarkFemaleHumansMaleMiddle AgedNeoplasm StagingPostoperative PeriodPrognosisRadionuclide ImagingReceptors, SomatostatinRetrospective StudiesReceptors, Somatostatin

Identifiers

PMID25671432
PMCPMC4324995
OpenAlexW2282415258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.